Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
March 30, 2021 at 07:13 pm
Share
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was TWD 1,543.589 million compared to TWD 1,156.642 million a year ago. Operating income was TWD 268.920 million compared to TWD 121.108 million a year ago. Net income was TWD 531.873 million compared to TWD 117.003 million a year ago. Basic earnings per share was TWD 6.86 compared to TWD 1.51 a year ago. Diluted earnings per share was TWD 6.79 compared to TWD 1.5 a year ago.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
